Samsung Epis Unit Signs U.S. Biosimilar Sales Agreement With Teva
A Samsung Epis unit signed an agreement with Teva for U.S. sales of its Remicade and Enbrel biosimilars, worth as much as $420 million.
Related stories
Waters Acquires Mobilion Systems
Waters said it acquired Mobilion Systems, adding ion-mobility separation technology to its mass spectrometry portfolio.
M impact | EQUITY | Nov 03, 2026, 10:56 AM UTC
Remedy Entertainment Swings to EUR 600,000 Q3 EBIT Profit
Q3 revenue more than tripled year on year to EUR 39.6 million.
M impact | EQUITY | Nov 03, 2026, 10:56 AM UTC
Remedyn Q3 Operating Profit Turns Positive
Remedyn Q3 2026 operating profit turned positive year over year, while revenue more than tripled.
M impact | EQUITY | Nov 03, 2026, 10:56 AM UTC
Kia America October Sales Rise 16%
Kia America said it achieved record overall and retail sales for a sixth consecutive month, driven by demand for electrified vehicles and hybrids. It sold 80,008 vehicles.
M impact | EQUITY | Nov 03, 2026, 10:54 AM UTC
Advanced Info Service Reports Quarterly Revenue of 58.06 Billion Baht
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Cosmo First Q2 Consolidated Revenue From Operations INR 13,878.6 Million
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC